NZNorbert Zilka

Norbert Zilka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Norbert Zilka has a total of 221 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasma Proteomic Profiling of Proteostatic and Redox Pathway Alterations Following a Multimodal Hormetic Intervention in Parkinson’s Disease

    by Alena Korencikova, Jakub Sofranko, Marian Grendar, Matej Gazdarica, Milan Grofik, Ivana Pilchova, Norbert Zilka, Michaela Skorvanova, Natalia Hunarova, Andrea Izarik Verespejova, et al.

    Parkinson’s disease (PD) is associated with systemic proteostatic failure, chronic neuroinflammation, and mitochondrial abnormalities linked to severe oxidative stress. This exploratory longitudinal study mapped the deep-coverage plasma proteome (~6000 proteins via SOMAmer technology) in 32 patients with mild-to-moderate PD following a 21-day intensive, multimodal physiological stimulus framework. This hormetic intervention combined balneo- and hydropinic therapy (incorporating mineral water with 7.48 mg/L H2S and peloid mud with 6.14% S2− of dry matter), neurophysiotherapy, a neuroprotective MIND diet, mindfulness meditation, and clinical aromatherapy. Systems-level pathway analysis was leveraged to evaluate alterations in functional biological networks. Gene Set Enrichment Analysis (GSEA) resolved a negative enrichment of the Parkinson’s disease pathway hsa05012 (FDR = 0.0053). Network topology modeling revealed a highly coordinated proteostatic and antioxidant alteration pattern involving interferon-gamma (IFN-γ) and polyubiquitin-B (UBB) protein clusters (p = 2.2 × 10−5), accompanied by the downregulation of protein clearance markers (UBB, p62, and UCHL1). Concurrently, upregulation of the phase-II detoxification modifier sulfotransferase 1C2 (SULT1C2; log2FC = 0.42) and a reduction of circulating mitochondrial respiratory subunits (NDUFB6, COX5A, NDUFB11) were observed. These exploratory findings may suggest that multimodal hormetic interventions trigger systemic, redox-responsive changes in protein signatures. However, because the distinct volatile chemical and organoleptic properties of the intervention prevent a sham control, these open-label findings must be treated as hypothesis-generating. These tentative models require verification in future parallel-controlled trials before definitive causal interpretations can be established.

  • Open Access

    Which assessment tools best distinguish between mild cognitive impairment and dementia? Lessons from a Slovak memory clinic cohort

    by Petr Novak, Stanislav Katina, Petra Brandoburova, Michaela Jezberova, Veronika Reznakova, Jozef Hanes, Frantisek Jurcaga, Peter Koson, Michal Novak, Linus Jönsson, et al.

    The utility of various cognitive assessment tools for distinguishing between mild impairment and dementia, as well as for determining cutoff values for specific populations, continues to be the subject of extensive research. Here, we assessed the utility and feasibility of these tools in the first Slovak memory clinic cohort. We enrolled a Slovak memory clinic cohort of patients with MCI and dementia (MCI, n = 84; dementia, n = 55). The participants were characterized using a range of cognitive assessment tools-Auditory Verbal Learning (AVLT), Category and Letter Fluency (CFT, LFT), Digit Span (DSF, DSB), Digit-Symbol Coding (DS-C), Frontal Assessment Battery (FAB), MMSE, MoCA, Rey Osterrieth Complex Figure (ROCF), and Trail Making Test (TMTA, TMTB); clinical assessments-Amsterdam Instrumental Activities of Daily Living (A-IADL) and 5-level EuroQol questionnaire with 5 dimensions (EQ-5D-5 L); and scales for anxiety, dependency, depression, dignity, and MRI volumetry. The ability of the various assessments to distinguish between MCI and dementia was evaluated. Over the course of three years, at a single memory clinic, it was feasible to enrol and evaluate a total of 150 participants, 139 of whom fulfilled the definition of either MCI or nonvascular dementia. Of the employed cognitive and clinical assessment tools, the best differentiation between MCI and dementia was observed for the AVLT and A-IADL. The DSF and DSB tests did not reveal differences between the populations. No differences were observed in education, vital signs, or anthropometric measurements. Participants with dementia had greater degrees of brain atrophy in the hippocampi and frontal, parietal, and temporal cortex; lower total brain volumes; and greater ventricular dilation. This study confirms the utility of a range of cognitive assessment tools and scales for differentiating between MCI and dementia but reveals that some commonly employed tools, such as the DSF and DSB, may not be sensitive to these differences. This study highlights the importance of accurate assessment of the ability to perform activities of daily living and supports the development of objective, ecologically valid assessments of IADL.

  • Open Access

    When Proteins Go MAD—Misfolded, Amplified, Detected: Advances in α-Synuclein Pathophysiology and RT-QuIC Detection

    by Naďa Labajová, Adam Polák, Ondrej Cehlár, Pavle Križan, Jozef Hritz, Martin Kolisek, Matej Škorvánek, Rostislav Škrabana, Branislav Kovačech, Norbert Žilka

    Α-Synuclein (α-Syn) aggregation and fibrillation are pathological hallmarks of several neurodegenerative disorders, collectively termed synucleinopathies. The misfolded α-Syn protein exhibits a prion-like seeding behavior, promoting misfolding, intracellular spread, and progressive neurodegeneration. Recent advances in structural biology have revealed critical insights into the conformational heterogeneity of α-Syn aggregates and their strain-specific properties across distinct synucleinopathies. In parallel, significant progress has been made in biomarker development, particularly with the arrival of seed amplification assays. Among these, Real-Time Quaking-Induced Conversion (RT-QuIC) has emerged as a highly sensitive, specific, and scalable method for detecting pathogenic α-Syn species in cerebrospinal fluid and other tissues. This review summarizes the latest findings from structural studies on α-Syn oligomers and aggregates, their relevance to disease mechanisms, and highlights RT-QuIC as the most clinically advanced and rapidly evolving assay. We discuss its potential for early, biomarker-driven diagnostics, patient stratification, and clinical implementation.

  • Open Access

    Micronutrient dynamics and deficiency risk across pregnancy and postpartum in a Slovak cohort

    by Alexandra Kristufkova, Neha Basheer, Katarina Koprdova, Matus Lieskovsky, Michal Fresser, Norbert Zilka

    Objective: To assess the dynamics in blood concentrations of vitamins (A, B6, B12, D, E,), trace elements such as selenium, magnesium, zinc, and iron (transferrin), and metabolite homocysteine during pregnancy and postpartum. Design: Cross-sectional, national cohort study conducted between January and June 2024. Setting: Slovakia. Population: Pregnant and postpartum women. Methods: From venous blood and capillary dry blood spot micronutrients were analysed using standard biochemical and biophysical methods. Main outcome measures: Group differences in blood micronutrient levels across pregnancy and postpartum. Results: Our findings reveal significant differences in maternal micronutrient levels across pregnancy and postpartum. While some nutrients, including vitamin D and folate, remained relatively stable, others such as vitamin A, B12, iron and zinc were observed at lower levels, and vitamin E at higher levels during pregnancy. Vitamin E levels in the 3rd trimester frequently exceeded reference values for the general adult population, whereas zinc levels were significantly lower postpartum. We observed high prevalence of vitamin B12 and iron deficiencies, as indicated by transferrin saturation, particularly in the 3rd trimester. Vitamin D deficiency was prevalent throughout pregnancy and postpartum. Finally, our analysis demonstrated that dried blood spot (DBS) technology provides comparable results to venous blood analysis for measuring vitamin A, D and homocysteine levels.

  • Open Access

    PET Imaging of a Transgenic Tau Rat Model SHR24 with [18F]AV1451

    by Nisha K. Ramakrishnan, Annie Ziyi Zhao, Stephen Thompson, Selena Milicevic Sephton, David J. Williamson, Tomáš Smolek, Norbert Žilka, Franklin I. Aigbirhio

    Purpose: Positron Emission Tomography (PET) scans with radioligands targeting tau neurofibrillary tangles (NFT) have accelerated our understanding of the role of misfolded tau in neurodegeneration. While intended for human research, applying these radioligands to small animals establishes a vital translational link. Transgenic animal models of dementia, such as the tau rat SHR24, play a crucial role in enhancing our understanding of these disorders. This study aims to evaluate the utility of SHR24 rat model for PET studies. Procedures: Dynamic PET scans were conducted in male SHR24 rats and their wild-type SHR (SHRwt) littermates using [18F]AV1451. Rapid blood sampling and metabolite analysis were performed to acquire input curves. Time activity curves were obtained from various brain regions over 60 min. Blood-based, 2-Tissue Compartment Model (2-TCM) and Logan graphical analysis were used to obtain kinetic modelling parameters. The ability of reference tissue models to predict the binding potential (BPND) were assessed. Autoradiography studies were performed to corroborate the scan data. Results: Total distribution volume (VT) was the best predicted parameter which revealed significantly higher uptake of [18F]AV1451 in the cortex (5.8 ± 1.1 vs 4.6 ± 0.7, P < 0.05) of SHR24 rats compared to SHRwt rats. Binding potential obtained from 2-TCM was variable, however BPND from reference tissue models detected significantly higher binding in cortex (0.28 ± 0.07 vs 0.20 ± 0.04, P < 0.01 by SRTM) and brainstem (0.14 ± 0.04 vs 0.08 ± 0.02, P < 0.01, by SRTM). Conclusions: With the ability to detect binding of established radioligand [18F]AV1451 in these rats, we have demonstrated the utility of this model for assessing aggregated tau neurobiology by PET, with reference tissue models providing potential for longitudinal studies.


  • Open Access

    Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217

    by Branislav Kovacech, Nicholas C. Cullen, Petr Novak, Jozef Hanes, Eva Kontsekova, Stanislav Katina, Vojtech Parrak, Michal Fresser, Jeroen Vanbrabant, Howard H. Feldman, et al.

    The spread of tau pathology closely correlates with the disease course and cognitive decline in Alzheimer’s disease (AD). Tau-targeting immunotherapies are being developed to stop the spread of tau pathology and thus halt disease progression. In this post hoc analysis of the ADAMANT clinical trial, we examined the performance of AADvac1, an active immunotherapy targeting the microtubule-binding region (MTBR) of tau, in a subgroup of participants with elevated plasma p-tau217, indicating AD-related neuropathological changes. ADAMANT was a 24-month, randomized, placebo-controlled, parallel-group, double-blinded, multicenter, phase 2 clinical trial in subjects with mild AD. The trial participants were randomized 3:2 to receive six doses of AADvac1 or placebo at 4-week intervals, followed by five booster doses at 14-week intervals. The primary outcome was safety. The secondary outcomes were the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer’s Disease Cooperative Study – Activities of Daily Living score for Mild Cognitive Impairment 18-item version (ADCS-ADL-MCI-18), and immunogenicity. Volumetric MRI, plasma neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) were exploratory outcomes. The inclusion criterion for this post-hoc analysis was a baseline plasma p-tau217 level above the cutoff for AD. Among 196 ADAMANT participants, 137 were positive for plasma p-tau217 (mean age 71.4 years, 59% women). AADvac1 was safe and well tolerated in this subgroup. AADvac1 reduced the rate of accumulation of log-plasma NfL by 56% and that of GFAP by 73%. The treatment differences in the CDR-SB and ADCS-ADL-MCI-18 scores favored AADvac1 but were not statistically significant. AADvac1 had no effect on whole-brain volume but nonsignificantly reduced the loss of brain cortical tissue in several regions. Importantly, the impact on the study outcomes was more pronounced in participants with higher anti-tau antibody levels. These results suggest that AADvac1 tau immunotherapy can reduce plasma biomarkers of neurodegeneration and neuroinflammation. These findings and possible observations on brain atrophy and cognition are hypothesis-generating and warrant further evaluation in a larger clinical trial. EudraCT 2015–000630-30 (primary) and NCT02579252.


  • Open Access

    Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models

    by Neha Basheer, Luc Buee, Jean-Pierre Brion, Tomas Smolek, Muhammad Khalid Muhammadi, Jozef Hritz, Tomas Hromadka, Ilse Dewachter, Susanne Wegmann, Isabelle Landrieu, et al.

    The transcellular propagation of the aberrantly modified protein tau along the functional brain network is a key hallmark of Alzheimer's disease and related tauopathies. Inoculation-based tau propagation models can recapitulate the stereotypical spread of tau and reproduce various types of tau inclusions linked to specific tauopathy, albeit with varying degrees of fidelity. With this systematic review, we underscore the significance of judicious selection and meticulous functional, biochemical, and biophysical characterization of various tau inocula. Furthermore, we highlight the necessity of choosing suitable animal models and inoculation sites, along with the critical need for validation of fibrillary pathology using confirmatory staining, to accurately recapitulate disease-specific inclusions. As a practical guide, we put forth a framework for establishing a benchmark of inoculation-based tau propagation models that holds promise for use in preclinical testing of disease-modifying drugs.


  • Open Access

    AD-TAU INDUCED TANGLE-LIKE PATHOLOGY IN A NEWLY CHARACTERIZED TRANSGENIC MOUSE MODEL

    by Muhammad Khalid Muhammadi, Tomáš Smolek, Ivana Uhrinova, Neha Basheer, Norbert Zilka

  • Top Cited Papers
    Open Access

    Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials

    by Neha Basheer, Tomáš Smolek, Imtaiyaz Hassan, Fei Liu, Khalid Iqbal, Norbert Zilka, Petr Novak

    Protein kinases (PKs) have emerged as one of the most intensively investigated drug targets in current pharmacological research, with indications ranging from oncology to neurodegeneration. Tau protein hyperphosphorylation was the first pathological post-translational modification of tau protein described in Alzheimer’s disease (AD), highlighting the role of PKs in neurodegeneration. The therapeutic potential of protein kinase inhibitors (PKIs)) and protein phosphatase 2 A (PP2A) activators in AD has recently been explored in several preclinical and clinical studies with variable outcomes. Where a number of preclinical studies demonstrate a visible reduction in the levels of phospho-tau in transgenic tauopathy models, no reduction in neurofibrillary lesions is observed. Amongst the few PKIs and PP2A activators that progressed to clinical trials, most failed on the efficacy front, with only a few still unconfirmed and potential positive trends. This suggests that robust preclinical and clinical data is needed to unequivocally evaluate their efficacy. To this end, we take a systematic look at the results of preclinical and clinical studies of PKIs and PP2A activators, and the evidence they provide regarding the utility of this approach to evaluate the potential of targeting tau hyperphosphorylation as a disease modifying therapy.


  • Open Access

    Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis

    by Miriam Fedičová, Pavol Mikula, Zuzana Gdovinová, Marianna Vitková, Norbert Žilka, Jozef Hanes, Lýdia Frigová, Jarmila Szilasiová

    Background and Objectives: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. Materials and Methods: Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). Results: The mean age of the study participants (n = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (p < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (p < 0.001; AUC: 0.839). Conclusions: Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients.